To test this, we systematically evaluated whether cabozantinib could modulate ferroptosis execution and radiosensitivity in NSCLC cell models, with a focus on the STAT3/MCL1/BECN1/SLC7A11 axis as a candidate mechanism. This evidence concerns the gene MCL1 and non-small cell lung carcinoma.